185 related articles for article (PubMed ID: 27659997)
1. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
Danese MD; Griffiths RI; Gleeson ML; Dalvi T; Li J; Mikhael JR; Deeter R; Dreyling M
Leuk Lymphoma; 2017 May; 58(5):1094-1104. PubMed ID: 27659997
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
3. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
4. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
6. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
7. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients.
Huntington S; Keshishian A; McGuire M; Xie L; Baser O
Leuk Lymphoma; 2018 Dec; 59(12):2880-2887. PubMed ID: 29936866
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Future Oncol; 2019 Mar; 15(9):1021-1034. PubMed ID: 30757910
[TBL] [Abstract][Full Text] [Related]
9. Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Li M; Li Y; Yin Q; Mi R; Chen L; Du J; Wei X
Leuk Lymphoma; 2014 Jul; 55(7):1578-83. PubMed ID: 24070424
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Park SI; Grover NS; Olajide O; Asch AS; Wall JG; Richards KL; Sobol AL; Deal AM; Ivanova A; Foster MC; Muss HB; Shea TC
Br J Haematol; 2016 Oct; 175(2):281-289. PubMed ID: 27448091
[TBL] [Abstract][Full Text] [Related]
11. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
Elstrom RL; Martin P; Ostrow K; Barrientos J; Chadburn A; Furman R; Ruan J; Shore T; Schuster M; Cerchietti L; Melnick A; Coleman M; Leonard JP
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):192-6. PubMed ID: 20511164
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
Jung YH; Woo IS; Han CW
Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
16. Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.
Koff JL; Rai A; Flowers CR
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e115-e121. PubMed ID: 29273217
[TBL] [Abstract][Full Text] [Related]
17. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Farooq U; Maurer MJ; Thompson CA; Thanarajasingam G; Inwards DJ; Micallef I; Macon W; Syrbu S; Lin T; Lin Y; Ansell SM; Nowakowski GS; Habermann TM; Cerhan JR; Link BK
Br J Haematol; 2017 Oct; 179(1):50-60. PubMed ID: 28653407
[TBL] [Abstract][Full Text] [Related]
18. Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma.
Sarid N; Joffe E; Gibstein L; Avivi I; Polliack A; Perry C; Herishanu Y
Leuk Lymphoma; 2016 Jul; 57(7):1633-9. PubMed ID: 26643787
[TBL] [Abstract][Full Text] [Related]
19. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
[TBL] [Abstract][Full Text] [Related]
20. Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile.
Tien YY; Link BK; Brooks JM; Wright K; Chrischilles E
Leuk Lymphoma; 2015 Jan; 56(1):65-71. PubMed ID: 24625326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
